Stock Events

Stock Events

Opgen 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14AugExpected
Q2 2025
Next
-1.21
-0.87
-0.54
-0.21
Expected EPS
N/A
Actual EPS
N/A

Financials

77.63%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
25.72MRevenue
19.97MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap22.27B
Guardant Health, Inc. specializes in liquid biopsies and cancer diagnostics, directly competing with Opgen's diagnostic solutions for detecting pathogens and antibiotic resistance genes.
Illumina
ILMN
Mkt Cap28.55B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, competing in the broader market of genomic analysis where Opgen also operates.
Qiagen NV
QGEN
Mkt Cap8.07B
Qiagen N.V. offers sample to insight solutions including infectious disease diagnostics, directly competing with Opgen's focus on molecular diagnostics.
Thermo Fisher Scientific
TMO
Mkt Cap194.52B
Thermo Fisher Scientific Inc. offers a wide range of diagnostics and research solutions, including those for infectious disease, competing with Opgen's diagnostic products.
Pacific Biosciences of California
PACB
Mkt Cap521.81M
Pacific Biosciences of California, Inc. provides sequencing systems that compete with Opgen's genomic analysis technologies.
Intellia Therapeutics
NTLA
Mkt Cap2.45B
Intellia Therapeutics, Inc. is involved in CRISPR technology for genetic editing, which could compete with Opgen's genomic approaches for diagnostics and treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, potentially competing with Opgen's treatments and diagnostics in genetic diseases.
Adaptive Biotechnologies
ADPT
Mkt Cap3.39B
Adaptive Biotechnologies Corp. focuses on the immune-driven medicine space, including diagnostics that could compete with Opgen's offerings in infection and resistance detection.

About

CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company offers Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; and collaboration services, including funded software arrangements. In addition, the company offers listing sponsorship and consultancy services. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026. CapForce Inc. was incorporated in 2001 and is headquartered in Clarksburg, Maryland.
Show more...
CEO
Mr. Christian-Laurent Benoit Bonte
Employees
3
Country
United States
ISIN
US68373L1098

Listings

MU
DE
6502.MU
STU
DE
650.STU
MU
DE
650.MU
LSE
GB
0A8L.LSE

0 Comments

Share your thoughts

FAQ

What is Opgen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Opgen stocks are traded under the ticker 650.STU.
When is the next Opgen earnings date?▼
Opgen is going to release the next earnings report on August 14, 2026.
What is Opgen revenue for the last year?▼
Opgen revenue for the last year amounts to 25.72M EUR.
What is Opgen net income for the last year?▼
650.STU net income for the last year is 19.97M EUR.
How many employees does Opgen have?▼
As of July 12, 2026, the company has 3 employees.
In which sector is Opgen located?▼
Opgen operates in the Other sector.
When did Opgen complete a stock split?▼
Opgen has not had any recent stock splits.
Where is Opgen headquartered?▼
Opgen is headquartered in Clarksburg, United States.